CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- 4 Grant or award Director acquired 67,000 shares (grant or award)
- 4 Grant or award Director acquired 31,188 shares (grant or award)
- 4 Grant or award Director acquired 23,643 shares (grant or award)
- 4 Grant or award Director acquired 21,127 shares (grant or award)
- 4 Grant or award Director acquired 42,507 shares (grant or award)
- 4 Open-market buy Director bought 164,000 shares at an average $1.97 ($323,693)
- 4 Open-market sale Director sold 4,000,000 shares at $2.15 ($8,600,000)
- 4/A Shares withheld for taxes Chief Executive Officer gave up 30,350 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 30,350 shares (to pay taxes)
- 4 Shares withheld for taxes President gave up 23,795 shares (to pay taxes)
- 4 Grant or award Chief Financial Officer acquired 200,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 869,565 shares (grant or award)
- 4 Grant or award Director acquired 86,956 shares (grant or award)
- 4 Conversion Director acquired 6,927,419 shares (conversion)
- 4 Grant or award Director acquired 79,504 shares (grant or award)
- 4 Grant or award Director acquired 79,504 shares (grant or award)
- 4 Grant or award Director acquired 79,504 shares (grant or award)
- 4 Grant or award Director acquired 79,504 shares (grant or award)
- 4 Grant or award Director acquired 79,504 shares (grant or award)
Page 3 of 21 · 403 filings